Cencora (NYSE:COR – Get Free Report) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 17.750-17.950 for the period, compared to the consensus estimate of 17.850. The company issued revenue guidance of -.
Cencora Stock Performance
Shares of COR stock opened at $313.86 on Friday. The company has a fifty day moving average price of $298.98 and a two-hundred day moving average price of $313.24. Cencora has a one year low of $244.82 and a one year high of $377.54. The stock has a market cap of $59.89 billion, a P/E ratio of 23.32, a P/E/G ratio of 1.80 and a beta of 0.57. The company has a debt-to-equity ratio of 3.53, a current ratio of 0.93 and a quick ratio of 0.58.
Cencora (NYSE:COR – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to analyst estimates of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $4.00 EPS. As a group, equities analysts predict that Cencora will post 17.84 EPS for the current year.
Cencora Dividend Announcement
Cencora declared that its Board of Directors has authorized a share repurchase program on Thursday, May 21st that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 3.9% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.
Analysts Set New Price Targets
Several analysts have issued reports on COR shares. William Blair initiated coverage on Cencora in a research note on Tuesday, April 28th. They issued a “market perform” rating on the stock. Wells Fargo & Company boosted their target price on Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Robert W. Baird set a $370.00 price target on Cencora in a research note on Thursday, August 6th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, August 6th. Finally, UBS Group lifted their price objective on shares of Cencora from $412.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $374.25.
View Our Latest Stock Analysis on Cencora
Insider Transactions at Cencora
In other news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was bought at an average price of $270.23 per share, for a total transaction of $148,626.50. Following the completion of the acquisition, the director directly owned 4,359 shares in the company, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.38% of the stock is owned by company insiders.
Institutional Trading of Cencora
Several institutional investors have recently added to or reduced their stakes in COR. Beacon Pointe Advisors LLC increased its position in Cencora by 1.1% during the 4th quarter. Beacon Pointe Advisors LLC now owns 3,492 shares of the company’s stock worth $1,180,000 after buying an additional 37 shares during the period. Parkside Financial Bank & Trust increased its position in Cencora by 2.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,784 shares of the company’s stock worth $603,000 after acquiring an additional 38 shares during the period. Sumitomo Life Insurance Co. raised its stake in Cencora by 0.9% in the 4th quarter. Sumitomo Life Insurance Co. now owns 4,462 shares of the company’s stock worth $1,507,000 after purchasing an additional 39 shares in the last quarter. Evergreen Capital Management LLC raised its stake in Cencora by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock worth $370,000 after purchasing an additional 45 shares in the last quarter. Finally, Mission Creek Capital Partners Inc. boosted its holdings in Cencora by 5.1% in the 4th quarter. Mission Creek Capital Partners Inc. now owns 1,158 shares of the company’s stock valued at $391,000 after purchasing an additional 56 shares during the period. 97.52% of the stock is currently owned by institutional investors.
About Cencora
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Read More
- Five stocks we like better than Cencora
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
